Nobel Biocare (NVST) - Long-Term Liabilities to Capital

Corporate emblem and logo of Nobel Biocare (NVST)

The price trend shown below for Envista Holdings (NVST) reflects the asset's dynamics, with a value of 0.48. The business relies on the development of advanced 3D dental modeling software and high-tech scanners. The company's environmental strategy is based on eliminating toxic materials from packaging and recycling equipment. Geopolitical risks are minimal, as the supply of humanitarian medical devices is carried out globally without trade restrictions.

Envista Holdings Corp - NVST Long-Term Debt to Capital (period 07/04/2022 - 11/01/2026)

Comprehensive metric breakdowns and analytics for Envista Holdings (NVST)

- stock value and consensus price forecast:
Stock Quotes Envista Holdings Corporation|NVST - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Envista Holdings|NVST - Enterprise Value
- book value of equity indicators:
Equity per Share Envista|NVST - Book Capitalization|Market Capitalization to Book Value envistaco.com|NVST - Company Total Assets
- debt and solvency information:
Total Debt to Equity Ratio Envista Holdings|NVST - Long-Term Debt to Capital|Short-Term Debt to Capital envistaco.com|NVST - Company Debts|Debt to Book Capitalization Ratio Envista Holdings|NVST - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Envista|Interim Coverage Ratio envistaco.com
- financial results and valuation multiples details:
NVST - Company Net Income
Comprehensive company analysis:Envista Holdings Corporation
Signature product of Envista Holdings

For Envista Holdings (NVST), a leader in the dental market, analyzing long-term credit leverage is critical given the limited room for pricing power due to competition. This long-term debt-to-equity ratio is calculated as the ratio of liabilities with a maturity of more than one year to shareholders' equity, allowing investors to assess the business's financial stability and default risk.

Competing companies

Long-Term Debt to Equity Ratio Intuitive Surgical, Inc. (ISRG)|Long-Term Debt to Capital DHR|BDX - Long-Term Liabilities to Capital|Long-Term Debt to Capital STE (STERIS plc)|WST: Long-Term Debt to Capital Ratio|Baxter - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Masimo Corp MASI|STVN: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Teleflex Corp|MMSI (Merit Medical Systems) - Long-Term Debt to Capital|Long-Term Debt to Capital icumed.com|Long-Term Debt to Equity Dentsply Sirona (XRAY)|Long-Term Debt to Equity LMAT (LeMaitre Vascular Inc)|AtriCure Corp - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient STAA|ChromaDex Corp. - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital zimvie.com ZIMV|AngioDynamics (ANGO) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio CERS|Long-Term Debt to Equity Alpha Teknova Inc|Monogram Orthopedics Inc. (MGRM) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio STSS (Sharps Technology, Inc.)|Long-Term Loans to Capital Ratio INFU|Long-Term Debt to Equity Utah Medical Products, Inc. UTMD|Long-Term Debt to Capital Coefficient KRMD|NYXH: Long-Term Debt to Equity Ratio|MBOT - Long-Term Debt to Capital|Pro-Dex, Inc. (PDEX) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio zentek.com|ELUT (Elutia) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Milestone Scientific Inc MLSS|Long-Term Debt to Equity NEXGEL, Inc (NXGL)|retractable.com - Long-Term Debt to Capital Ratio|Harvard Bioscience, Inc. - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio FEMY (femasys.com)|MHUA - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Predictive Oncology POAI|CJMB: Long-Term Debt to Capital|Long-Term Liabilities to Capital Atrion Corporation Inc. (ATRI)|Long-Term Debt to Equity NeuroMetrix, Inc.